Toma S, Palumbo R, Sogno G, Canavese G, Barra S, Marziano C, Serrano J, Albanese E, Rosso R
Division of Medical Oncology, Genoa University, Italy.
Anticancer Res. 1991 Nov-Dec;11(6):2085-9.
Doxorubicin was administered by continuous infusion at a dosage of 12 mg/sqm/day for 5 days concomitantly with radiation treatment (150 or 200 cGy/day for trunk or extremity lesions, respectively) for 5 days. The 5-day cycles were repeated every 3 weeks. Seventeen patients, 5 of whom were pretreated, entered the study; all were assessable for toxicity and 15 for response. The overall objective response rate was 46% (7/15): 1 complete and 6 partial responses. Response rate reached 54% in only non-pretreated patients (6/11) and 75% in patients with PS less than or = 2 (6/8). No disease progression was observed during treatment. The median duration of complete or partial responses was 28 weeks (range 5-86). Toxicity was low and treatment very well tolerated. In our preliminary analysis, the response rate obtained with this combined chemo-radiotherapic regimen was encouraging and the toxicity was acceptable.
多柔比星通过持续输注给药,剂量为12毫克/平方米/天,持续5天,同时进行放射治疗(躯干或四肢病变分别为每天150或200厘戈瑞),持续5天。每3周重复一次为期5天的周期。17名患者进入研究,其中5名曾接受过预处理;所有患者均可评估毒性,15名可评估疗效。总体客观缓解率为46%(7/15):1例完全缓解,6例部分缓解。仅未接受过预处理的患者缓解率达到54%(6/11),体力状态评分小于或等于2的患者缓解率为75%(6/8)。治疗期间未观察到疾病进展。完全或部分缓解的中位持续时间为28周(范围5 - 86周)。毒性较低,治疗耐受性良好。在我们的初步分析中,这种联合放化疗方案所获得的缓解率令人鼓舞,且毒性可以接受。